4//SEC Filing
McKenna Mark C. 4
Accession 0001213900-25-074368
CIK 0001869105other
Filed
Aug 10, 8:00 PM ET
Accepted
Aug 11, 5:01 PM ET
Size
8.2 KB
Accession
0001213900-25-074368
Insider Transaction Report
Form 4
McKenna Mark C.
Other
Transactions
- Exercise/Conversion
Class B ordinary shares
2025-08-11−30,000→ 0 total→ Class A ordinary shares (30,000 underlying) - Exercise/Conversion
Common Stock
2025-08-11+30,000→ 30,000 total
Footnotes (1)
- [F1]In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.
Documents
Issuer
BridgeBio Oncology Therapeutics, Inc.
CIK 0001869105
Entity typeother
Related Parties
1- filerCIK 0001749623
Filing Metadata
- Form type
- 4
- Filed
- Aug 10, 8:00 PM ET
- Accepted
- Aug 11, 5:01 PM ET
- Size
- 8.2 KB